Pliant Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · South San Francisco, CA
PLRX chart
What traders are saying about $PLRX
Latest postsPliant Therapeutics, Inc. news
- David Raben: Challenging the Treatment Paradigm in Extensive-Stage SCLC With Tarlatamab
Oncodaily ·
- Pliant Therapeutics, Inc. Estimates – NASDAQ:PLRX
TradingView ·
- Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
Yahoo Finance ·
- Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Yahoo Finance ·
- Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Yahoo Finance ·
- Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
Yahoo Finance ·
- Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Yahoo Finance ·
- Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Yahoo Finance ·
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Yahoo Finance ·
- Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Yahoo Finance ·
- Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Yahoo Finance ·
- Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Yahoo Finance ·
Pliant Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M |
| Net income | $149.3M | $210.3M | $161.3M | -$123.3M |
| Diluted EPS | $-2.43 | $-3.47 | $-2.75 | $-2.94 |
| Total assets (year end) | $225.2M | $396.9M | $512.2M | $350.6M |
| Cash and equivalents (year end) | $45.4M | $71.2M | $63.2M | $33.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Pliant Therapeutics, Inc.
- Ticker
- PLRX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1746473
Frequently asked questions
What exchange is Pliant Therapeutics, Inc. listed on?
Pliant Therapeutics, Inc. trades on the Nasdaq under the ticker symbol PLRX.
What industry is Pliant Therapeutics, Inc. in?
Pliant Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Pliant Therapeutics, Inc. headquartered?
Pliant Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Pliant Therapeutics, Inc.'s fiscal year end?
Pliant Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Pliant Therapeutics, Inc. report?
Pliant Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.